BrainStorm Cell Therapeutics Inc. Receives US Notice Of Allowance For Its Key Stem Cell Technology Patent
2/3/2014 8:41:22 AM
NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has received a Notice of Allowance from the U.S. Patent Office for its “Mesenchymal Stem Cells for the Treatment of CNS Diseases” (serial number 12/994,761) patent application.
Help employers find you! Check out all the jobs and post your resume.
comments powered by